A
ABLi Therapeutics develops small molecule inhibitors targeting Abelson Tyrosine Kinases (Abl kinases) to intervene in neurodegenerative diseases. The company uses its proprietary Re-engineering Approach with Metabolism Preserved (RAMP™) engine to design novel candidates with enhanced brain penetration. This focus aims to create disease-modifying treatments for conditions like Parkinson’s disease associated with Abl kinase dysfunction.
Updated 2 months ago
Funding
Funding not disclosed
Funding rounds are not available yet.
Founders
Founder details are not available yet.
Product
Features
- ABLi Therapeutics develops small molecule inhibitors targeting Abelson Tyrosine Kinases (Abl kinases) to intervene in neurodegenerative diseases. The company uses its proprietary Re-engineering Approach with Metabolism Preserved (RAMP™) engine to design novel candidates with enhanced brain penetration and improved safety profiles. Their focus is on engineering selective Abl inhibitors to treat conditions like Parkinson’s disease associated with Abl kinase dysfunction.